| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of AbCellera Biologics (NASDAQ:ABCL) through any online brokerage.
Other companies in AbCellera Biologics’s space includes: Thermo Fisher Scientific Inc (NYSE:TMO), Danaher Corp (NYSE:DHR), Agilent Technologies Inc (NYSE:A), IQVIA Holdings Inc (NYSE:IQV) and Waters Corp (NYSE:WAT).
AbCellera Biologics has a consensus price target of $13.18.
The stock price for AbCellera Biologics (NASDAQ: ABCL) is $12.56 last updated October 13, 2026 at 2:25 PM EDT.
There are no upcoming dividends for AbCellera Biologics.
AbCellera Biologics does not have any upcoming earnings scheduled.
There is no upcoming split for AbCellera Biologics.
AbCellera Biologics is in the Health Care sector and Life Sciences Tools & Services industry. They are listed on the NASDAQ.
